Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings.

BERLIN — Berlin is trying to stop Washington from persuading a German company seeking a coronavirus vaccine to move its research to the United States, prompting German politicians to insist no country should have a monopoly on any future vaccine.

German government sources told Reuters on Sunday that the U.S. administration was looking into how it could gain access to a potential vaccine being developed by a German firm, CureVac.

Earlier, the Welt am Sonntag German newspaper reported that President Donald Trump had offered funds to lure CureVac to the United States, and the German government was making counter-offers to tempt it to stay.

"The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe," a Health Ministry spokeswoman said, confirming a quote in the newspaper.

"In this regard, the government is in intensive exchange with the company CureVac," she added.

A senior American official later said the Welt report was wrong.

"Not true. The Welt story was wrong," said Richard Grenell, acting Director of National Intelligence and the U.S. Ambassador to Germany, referring to the newspaper report.

"Now everyone is back peddling," he added on Twitter.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings. This site is protected by recaptcha

Not true. The Welt story was wrong. But Business Insider, Reuters and others went with it anyway despite not having their own sources. Now everyone is back peddling. https://t.co/88UohluwTj — Richard Grenell (@RichardGrenell) March 15, 2020

A German Economy Ministry spokeswoman also said Berlin "has a great interest" in producing vaccines in Germany and Europe.

She declined to comment on any takeover possibilities but referred to Germany's foreign trade law, under which Berlin can examine takeover bids from non-EU, so-called third countries "if national or European security interests are at stake."

In a statement issued Sunday, the company said it "rejects current rumors of an acquisition."

The statement added that while it was in contact with "authorities worldwide," it "abstains from commenting on speculations and rejects allegations about offers for acquisition of the company or its technology."

A spokesperson for CureVac also denied the report. "To make it clear again on coronavirus: CureVac has not received from the U.S. government or related entities an offer before, during and since the Task Force meeting in the White House on March 2. CureVac rejects all allegations from press," the spokesperson said.

Florian von der Muelbe, CureVac's chief production officer and co-founder, told Reuters last week the company had started with a multitude of coronavirus vaccine candidates and was now selecting the two best to go into clinical trials.

The privately-held company based in Tuebingen, Germany, hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans.

On its website, CureVac said CEO Daniel Menichella early this month met with Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and senior representatives of pharmaceutical and biotech companies to discuss a vaccine.

Karl Lauterbach, a professor of health economics and epidemiology who is also a senior lawmaker with Germany's Social Democrats, tweeted in reaction to the Welt am Sonntag report: "The exclusive sale of a possible vaccine to the USA must be prevented by all means. Capitalism has limits."

CureVac in 2015 and 2018 secured financial backing for development projects from the Bill & Melinda Gates Foundation, working on shots to prevent malaria and influenza.

In the field of so-called mRNA therapeutics, CureVac competes with U.S. biotech firm Moderna and German rival BioNTech, which Pfizer has identified as a potential collaboration partner.

Drugs based on mRNA provide a type of genetic blueprint that can be injected into the body to instruct cells to produce the desired therapeutic proteins. That contrasts with the conventional approach of making these proteins in labs and bio-reactors.

In the case of vaccines, the mRNA prompts body cells to produce so-called antigens, the tell-tale molecules on the surface of viruses, that spur the immune system into action.

Companies working on other coronavirus-vaccine approaches include Johnson & Johnson and INOVIO Pharmaceuticals, Inc.

CLARIFICATION (March 16, 2020, 8 a.m. ET): An earlier version of this story included information that did not meet NBC News' editorial standards. This information has been removed.